Cargando…

Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant

BACKGROUND: Advances in allogeneic hematopoietic stem cell transplant (HSCT) have increased patient survival, although substantial treatment-related toxicity remains, including chronic kidney disease (CKD). We assessed the association between CKD and survival and transplant-specific outcomes in HSCT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelletier, Karyne, Côté, Gabrielle, Madsen, Kayla, Chen, Shiyi, Kim, S Joseph, Chan, Christopher T, Mattsson, Jonas, Pasic, Ivan, Kitchlu, Abhijat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308100/ https://www.ncbi.nlm.nih.gov/pubmed/35892015 http://dx.doi.org/10.1093/ckj/sfac091

Ejemplares similares

Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events
por: Rao Ullur, Avinash, et al.
Publicado: (2023)

CKD After 225Ac-PSMA617 Therapy in Patients With Metastatic Prostate Cancer
por: Pelletier, Karyne, et al.
Publicado: (2020)

Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation
por: Liu, Yao-Chung, et al.
Publicado: (2016)

Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma
por: Côté, Gabrielle, et al.
Publicado: (2023)

Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma
por: Jeon, Young-Woo, et al.
Publicado: (2019)

Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report
por: Hamilton, Betty K, et al.
Publicado: (2013)

P569: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PREGNANT WOMEN WITH ACUTE MYELOID LEUKEMIA
por: Troitskaya, Vera, et al.
Publicado: (2023)

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
por: Muranushi, Hiroyuki, et al.
Publicado: (2020)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse‐free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia
por: Chang, Jeremy, et al.
Publicado: (2019)

Inferences for current chronic graft-versus-host-disease free and relapse free survival
por: Zhang, Xu, et al.
Publicado: (2022)

The Impact of Pre-transplant Cell-free DNA Levels on Leukemia Relapse and Transplant-related Complications in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Yegin, Zeynep Arzu, et al.
Publicado: (2020)

Lymphocyte recovery is an independent predictor of relapse in allogeneic hematopoietic cell transplantation recipients for acute leukemia
por: Damlaj, Moussab, et al.
Publicado: (2017)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Yong, Michelle K., et al.
Publicado: (2017)

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
por: Rodríguez-Arbolí, Eduardo, et al.
Publicado: (2022)

Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation
por: Lin, Ren, et al.
Publicado: (2013)

Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
por: Godfrey, James, et al.
Publicado: (2022)

Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia
por: Chen, Huan, et al.
Publicado: (2012)

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)

Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT
por: Devillier, Raynier, et al.
Publicado: (2023)

Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation
por: Minculescu, Lia, et al.
Publicado: (2019)

Relapse-free survival in Sudanese women with non-metastatic breast cancer
por: Muddather, Hiba Faroug, et al.
Publicado: (2022)

Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review
por: Kitchlu, Abhijat, et al.
Publicado: (2021)

Factors Having an Impact on Relapse and Survival in Transplant Recipients With Alcohol-Induced Liver Disease
por: Schneekloth, Terry D., et al.
Publicado: (2021)

Pegylated Liposomal Doxorubicin and Kidney-Limited Thrombotic Microangiopathy in a Kidney Transplant Recipient: A Case Report
por: Rodriguez-Ramirez, Sonia, et al.
Publicado: (2022)

The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
por: Maffini, Enrico, et al.
Publicado: (2022)

Interleukin-10-592 polymorphism: impact on relapse and survival after allogeneic hematopoietic stem cell transplantation in children with hematological malignancies
por: Schwenk, Laura, et al.
Publicado: (2021)

Sarcopenia is associated with worse surgical complications but not relapse-free survival and overall survival in patients with retroperitoneal liposarcoma
por: Zhao, Mingkun, et al.
Publicado: (2022)

Accidental Morcellation of Uterine Leiomyosarcoma Influences Relapse Free Survival but Does Not Negatively Influence Overall Survival
por: Reichert, Verena M. C., et al.
Publicado: (2023)

Does treating with anti–PD-1 to improve glomerular health come without a cost?
por: Jhaveri, Kenar D., et al.
Publicado: (2022)

Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients
por: Johansson, Inger, et al.
Publicado: (2015)

Donor–Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation
por: Kum, Elena, et al.
Publicado: (2021)

Cutaneous Legionella infections in allogeneic hematopoietic cell transplantation recipients
por: Vaidya, Toral, et al.
Publicado: (2020)

T cell receptor excision circles are potential predictors of survival in adult allogeneic hematopoietic stem cell transplantation recipients with acute myeloid leukemia
por: Söderström, Anna, et al.
Publicado: (2022)

Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients
por: Ogimi, Chikara, et al.
Publicado: (2022)

Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease
por: Gong, Di-He, et al.
Publicado: (2016)

Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission
por: Yoon, Jae-Ho, et al.
Publicado: (2016)

Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
por: Schierbeck, Frederikke, et al.
Publicado: (2022)

Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
por: Daull, Anne-Marie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_81mbdbmcftj28j5vjl4bjsqt41